Company news

Apellis Pharmaceuticals, Inc. news in 2023

Apellis Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference

December 27, 2023

Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

December 13, 2023

EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting

December 10, 2023

Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference

November 20, 2023

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)

November 3, 2023

Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results

October 31, 2023

Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results

October 24, 2023

The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)

October 19, 2023

Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week

October 16, 2023

Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023

October 4, 2023

Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

October 1, 2023

Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023

September 24, 2023

Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success

August 28, 2023

Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)

August 21, 2023

Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results

July 30, 2023

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)

July 29, 2023

Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy

July 28, 2023

Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results

July 23, 2023

Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

July 9, 2023

Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

June 6, 2023

Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS

May 24, 2023

Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results

May 3, 2023

Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference

May 2, 2023

Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results

April 26, 2023

Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy

April 22, 2023

Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy

April 20, 2023

Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign

April 16, 2023

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares

February 26, 2023

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

February 21, 2023

Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

February 21, 2023

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

February 20, 2023

FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness

February 16, 2023

Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

January 4, 2023

Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Calls in 2023

Decks in 2023